Bioverativ Starts Making Deals

In February, Biogen Inc. (NASDAQ: BIIB) completed the previously announced spin-off of its global hemophilia business. The new company, known as Bioverativ (NASDAQ: BIVV), is an independent, publicly traded global biotechnology company focused on hemophilia and other rare blood disorders. Bioverativ went on to announce the largest biotech deal of May 2017. On May 22, it acquired privately held True North Therapeutics for an upfront payment of $400 million plus assumed cash. True North investors are eligible to receive additional payments of up to $425 million contingent on the achievement of future development, regulatory and sales milestones of its lead product. Based in... Read More »